Open label study of the effect of daily treatment with MPC-7869 in subjects with dementia of the Alzheimer's type.
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2012
At a glance
- Drugs Tarenflurbil (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- 28 Apr 2012 Planned number of patients changed from 1000 to 1661 as reported by European Clinical Trials Database.
- 01 Aug 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 09 May 2007 New trial record.